CMPR vs NBIX · P/E 8.2, rev $3.74B vs P/E 45, rev $2.36B
Cimpress NV (CMPR) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Cimpress NV (CMPR) is a specialty business services company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CMPR revenue for 2026-06-30 was $3.74B. Net income was $95.9M. Revenue was up 9.8% from 2025-06-30 to 2026-06-30. CMPR currently screens at market cap $1.19B and trailing P/E 8.2.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CMPR currently screens at market cap $1.19B and trailing P/E 8.2. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CMPR and NBIX stock pages for the full models.
Not investment advice.